ZIM Laboratories Limited (BOM:541400)
102.00
+1.97 (1.97%)
At close: May 26, 2026
ZIM Laboratories Revenue
In the fiscal year ending March 31, 2026, ZIM Laboratories had annual revenue of 3.74B INR, down -1.25%. ZIM Laboratories had revenue of 1.05B in the quarter ending March 31, 2026, a decrease of -3.27%.
Revenue
3.74B
Revenue Growth
-1.25%
P/S Ratio
1.46
Revenue / Employee
6.49M
Employees
577
Market Cap
5.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.74B | -47.33M | -1.25% |
| Mar 31, 2025 | 3.79B | 116.16M | 3.16% |
| Mar 31, 2024 | 3.68B | -310.92M | -7.80% |
| Mar 31, 2023 | 3.99B | 651.00M | 19.52% |
| Mar 31, 2022 | 3.34B | 261.64M | 8.51% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anuh Pharma | 7.72B |
| Sudarshan Pharma Industries | 7.12B |
| Kopran | 6.81B |
| Fermenta Biotech | 5.44B |
| Bharat Parenterals | 3.45B |
| Albert David | 3.34B |
| Amanta Healthcare | 2.91B |
| Kilitch Drugs (India) | 2.35B |
ZIM Laboratories News
- 6 months ago - Why ZIM Laboratories has received CDSCO approval for its new Naproxen + Esomeprazole capsules - Business Upturn
- 10 months ago - ZIM Laboratories secures marketing authorization in Australia for urology drug combination - Business Upturn
- 11 months ago - ZIM Laboratories shares in focus as company gets first marketing approval in Australia - Business Upturn